EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition
This article was originally published in The Pink Sheet Daily
Executive SummaryBuyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.
You may also be interested in...
EUSA Pharma announced the launch of operations March 23 with a group of products acquired from Jazz Pharmaceuticals and funding from equity investor Essex Woodlands; it is the third specialty pharma company set up by U.K. entrepreneur Bryan Morton.
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.
Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.